CoChat

Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity

Open access

The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.

Abstract

Metabolic disorders, including obesity, diabetes, and cardiovascular disease, are widespread in Westernized nations. Gut microbiota composition is a contributing factor to the susceptibility of an individual to the development of these disorders; therefore, altering a person's microbiota may ameliorate disease. One potential microbiome-altering strategy is the incorporation of modified bacteria that express therapeutic factors into the gut microbiota. For example, N-acylphosphatidylethanolamines (NAPEs) are precursors to the N-acylethanolamide (NAE) family of lipids, which are synthesized in the small intestine in response to feeding and reduce food intake and obesity. Here, we demonstrated that administration of engineered NAPE-expressing E. coli Nissle 1917 bacteria in drinking water for 8 weeks reduced the levels of obesity in mice fed a high-fat diet. Mice that received modified bacteria had dramatically lower food intake, adiposity, insulin resistance, and hepatosteatosis compared with mice receiving standard water or control bacteria. The protective effects conferred by NAPE-expressing bacteria persisted for at least 4 weeks after their removal from the drinking water. Moreover, administration of NAPE-expressing bacteria to TallyHo mice, a polygenic mouse model of obesity, inhibited weight gain. Our results demonstrate that incorporation of appropriately modified bacteria into the gut microbiota has potential as an effective strategy to inhibit the development of metabolic disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci72517

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 76 references

Research works printed but not linked: 3

  1. Kramer, 1989, Int J Obes., 13, 123
  2. Wadden, 1989, Int J Obes., 13, 39
  3. Harris, 2012, J Obes., 2012, 879151

Cited by

See all 288

Metadata

Authors
Chen, Z., Guo, L., Zhang, Y., L. Walzem, R., Pendergast, J. S., Printz, R. L., Morris, L. C., Matafonova, E., Stien, X., Kang, L., Coulon, D., McGuinness, O. P., Niswender, K. D., & Davies, S. S.
Affiliations
  • Vanderbilt University (US)
  • Centre National de la Recherche Scientifique (FR)
Corresponding author
Davies, Sean S.
Venue
Journal of Clinical Investigation
Published
2014-06-24
Volume
124
Issue
8
Pages
3391-3406
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2076877166
Cited by
277
References
76
Citations by year
2026: 12 · 2025: 11 · 2024: 19 · 2023: 22 · 2022: 31 · 2021: 26 · 2020: 26 · 2019: 22 · 2018: 18 · 2017: 35 · 2016: 29 · 2015: 23 · 2014: 3
FWCI
12.31
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Discovery Research Portal (University of Dundee) (publishedVersion)
Funders
  • National Institutes of Health (1dp2od003137-01, 5p60dk020593-31)
  • National Institute of Diabetes and Digestive and Kidney Diseases (P60-DK020593, U24DK092993, DK59637, DK 20593, U24DK059637, P30DK058404, P30DK020593)
  • National Center for Research Resources (UL1RR024975)
  • National Center for Complementary and Integrative Health (R01AT007830, AT07830)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
Keywords
obesity, gut microbiota, engineered bacteria, N-acylphosphatidylethanolamine, Escherichia coli Nissle 1917, high-fat diet, dietary intake, insulin resistance, hepatic steatosis, metabolic disorders, microbiome engineering
MeSH terms
Acyltransferases, Animals, Digestive System, Disease Models, Animal, DNA-Binding Proteins, Eating, Escherichia coli, Female, Humans, Liver, Male, Mice, Inbred C57BL, Obesity, Phosphatidylethanolamines, Recombinant Proteins, Weight Gain, Arabidopsis Proteins, Mice, Diet, High-Fat, Microbiota

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity. https://app.cochat.ai/papers/10.1172/jci72517
The paper
Chen, Z., Guo, L., Zhang, Y., L. Walzem, R., Pendergast, J. S., Printz, R. L., Morris, L. C., Matafonova, E., Stien, X., Kang, L., Coulon, D., McGuinness, O. P., Niswender, K. D., & Davies, S. S. (2014). Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity. Journal of Clinical Investigation. https://doi.org/10.1172/jci72517

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.